BPC-157
Promotes blood vessel formation, enhances tissue granulation, and modulates nitric oxide signaling for vascular support to damaged tissue.
- Promotes blood vessel formation
- Enhances tissue granulation
- Modulates nitric oxide signaling

Skin Renewal Blend
Same day / next business day dispatch
Free Shipping on orders over $200
Glow is a blend. Several peptides are combined and freeze-dried into a single 70 mg vial, chosen from compounds studied in skin and connective tissue models. Research on the individual ingredients covers collagen production, tissue structure, and how skin cells move and multiply. It is supplied for researchers testing several pathways together rather than one at a time.
Three-peptide research blend: BPC-157 + TB-500 + GHK-Cu
The pathways Glow acts on — and what each one does. Signalling pathways studied in preclinical models · illustrative.
Promotes blood vessel formation, enhances tissue granulation, and modulates nitric oxide signaling for vascular support to damaged tissue.
Increases cell migration, supports cytoskeletal remodeling, and reduces fibrotic scarring through thymosin beta-4 pathway activation.
Stimulates type I & III collagen synthesis, modulates 4,000+ genes, and delivers copper to repair sites for extracellular matrix rebuilding.
The main areas Glow is being studied for — and the study-reported figures behind them.
GHK-Cu promotes collagen synthesis while BPC-157 and TB-500 support epithelial repair and reduce scarring.
Pickart & Margolina 2018
TB-500 facilitates actin remodeling; BPC-157 promotes tendon fibroblast viability; GHK-Cu supports vascularization.
Chi et al. 2017
All three peptides demonstrate anti-inflammatory properties through different mechanisms in animal models.
Hsieh et al. 2016
Coordinated extracellular matrix deposition for functional, less fibrotic tissue regeneration.
Brcic et al. 2011
Representative figures from published research. Bars fill as you scroll.
Figures are representative of published research findings and shown for reference.
Every batch of Glow is sent to an accredited independent laboratory before it ships. Here is what we screen for.
| Components | BPC-157 + TB-500 + GHK-Cu |
|---|---|
| Strength | 70mg |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified per component) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Light Sensitivity | Protect from direct light at all times |
| Solubility | Water-soluble |
| COA | Included with every order |
| Appearance | White to off-white powder |
| Stability | 24 months from manufacture date when stored properly |
GLOW is a research peptide blend containing three complementary peptides: BPC-157 (Body Protection Compound), TB-500 (Thymosin Beta-4), and GHK-Cu (copper peptide). Each targets a different phase of tissue regeneration — vascular support, cell migration, and collagen synthesis respectively.
In preclinical research, BPC-157 promotes blood vessel formation (angiogenesis) to deliver nutrients to damaged tissue. TB-500 enhances cell migration to injury sites through actin regulation. GHK-Cu stimulates collagen production and modulates over 4,000 genes involved in tissue remodeling. Together they address three distinct but complementary phases of regeneration.
No. GLOW is not approved by the FDA for any medical use. It is sold exclusively for in vitro laboratory research purposes. The individual components have varying levels of preclinical evidence but no completed human clinical trials for the combined blend.
Store lyophilized (powder) form at -20°C for maximum stability. Protect from direct light at all times and avoid repeated freeze-thaw cycles.
Each component undergoes independent third-party testing including HPLC (High Performance Liquid Chromatography) for purity verification, mass spectrometry for molecular weight confirmation, and endotoxin testing. Certificates of Analysis are included with every order.
The evidence is based on individual component research: BPC-157 has 200+ preclinical publications, TB-500 has 170+ publications, and GHK-Cu has 130+ publications. The combined blend has not been studied as a single formulation in clinical trials. Synergy is inferred from mechanistic complementarity.
Independent published research indexed from PubMed and peer-reviewed journals — not Zorva Lab claims.
For Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Back to catalog